An “Age” Structured Model of Hematopoietic Stem Cell Organization with Application to Chronic Myeloid Leukemia
暂无分享,去创建一个
[1] O. Diekmann,et al. The Dynamics of Physiologically Structured Populations , 1986 .
[2] Kendall E. Atkinson. An introduction to numerical analysis , 1978 .
[3] S. Forman,et al. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. , 2007, Cancer research.
[4] Doron Levy,et al. A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia , 2008, Bulletin of mathematical biology.
[5] N. Cross,et al. Detection and quantification of residual disease in chronic myelogenous leukemia , 2000, Leukemia.
[6] M. Loeffler,et al. Stem Cell Fate Analysis Revisited: Interpretation of Individual Clone Dynamics in the Light of a New Paradigm of Stem Cell Organization , 2007, Journal of biomedicine & biotechnology.
[7] K. Antman,et al. Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.
[8] Ingo Roeder,et al. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. , 2002, Experimental hematology.
[9] Branford,et al. Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics , 1999, British journal of haematology.
[10] C. Eaves,et al. Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate , 2006, Clinical Cancer Research.
[11] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[12] Ingo Roeder,et al. Competitive clonal hematopoiesis in mouse chimeras explained by a stochastic model of stem cell organization. , 2005, Blood.
[13] Ajoy Ghatak,et al. The Dirac Delta Function , 2004 .
[14] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[15] Ingo Roeder,et al. Tissue Stem Cells: Definition, Plasticity, Heterogeneity, Self-Organization and Models – A Conceptual Approach , 2002, Cells Tissues Organs.
[16] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.
[17] I. Glauche,et al. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.
[18] K. B. Oldham,et al. An Atlas of Functions. , 1988 .
[19] Michael Cross,et al. Lineage Specification of Hematopoietic Stem Cells: Mathematical Modeling and Biological Implications , 2007, Stem cells.
[20] Doron Levy,et al. Modeling Imatinib-Treated Chronic Myelogenous Leukemia: Reducing the Complexity of Agent-Based Models , 2008, Bulletin of mathematical biology.
[21] R. LeVeque. Numerical methods for conservation laws , 1990 .
[22] Michael C Mackey,et al. A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.
[23] Begnaud Francis Hildebrand,et al. Introduction to numerical analysis: 2nd edition , 1987 .
[24] M. Loeffler,et al. Mathematical Modeling of Genesis and Treatment of Chronic Myeloid Leukemia , 2008, Cells Tissues Organs.
[25] Ingo Roeder,et al. Asymmetry of stem cell fate and the potential impact of the niche , 2006, Stem Cell Reviews.
[26] Michael Luck,et al. Understanding agent systems, Second Edition , 2004, Springer series on agent technology.
[27] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[28] Michael Luck,et al. Understanding Agent Systems , 2001, Springer Series on Agent Technology.
[29] P. Vigneri,et al. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.
[30] F. Michor,et al. Reply: The long-term response to imatinib treatment of CML , 2007, British Journal of Cancer.
[31] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.